Compare · BDX vs BVS
BDX vs BVS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Bioventus Inc. (BVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and BVS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $40.72B, about 53.9x BVS ($756.0M).
- Over the past year, BDX is down 14.6% and BVS is up 30.3% - BVS leads by 44.9 points.
- BVS has been more active in the news (16 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 14 for BVS).
- Company
- Becton Dickinson and Company
- Bioventus Inc.
- Price
- $147.72-0.05%
- $8.77-3.15%
- Market cap
- $40.72B
- $756.0M
- 1M return
- +0.01%
- -13.68%
- 1Y return
- -14.60%
- +30.31%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 16
- Recent ratings
- 25
- 14
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Bioventus Inc.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest BVS
- Director Bartholdson John A. converted options into 32,282 shares, increasing direct ownership by 41% to 111,902 units (SEC Form 4)
- Director Sutter Martin P converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Stalnecker Susan M converted options into 32,282 shares, increasing direct ownership by 30% to 138,239 units (SEC Form 4)
- Director Nohra Guy P converted options into 32,282 shares, increasing direct ownership by 28% to 148,892 units (SEC Form 4)
- Director Neels Guido J converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Hawkins William A converted options into 39,789 shares, increasing direct ownership by 15% to 297,640 units (SEC Form 4)
- Director Ladone Mary Kay converted options into 32,282 shares, increasing direct ownership by 41% to 111,263 units (SEC Form 4)
- Director Mcmurry-Heath Michelle converted options into 32,282 shares, increasing direct ownership by 72% to 77,279 units (SEC Form 4)
- Director Cowdy Philip G. converted options into 32,282 shares, increasing direct ownership by 276% to 43,982 units (SEC Form 4)
- Director Beyer Pat converted options into 32,282 shares, increasing direct ownership by 42% to 108,718 units (SEC Form 4)